TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Investing.com - Tempest Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Tempest Therapeutics announced earnings per share of $-0.6600 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.7600 on revenue of $0.00.
Tempest Therapeutics 's are down 41.36% and is trading at $1.6200 , still down 86.83% from its 52 week high of $12.30 set on Tuesday, November 9, 2021.
Tempest Therapeutics shares lost 10.99% to trade at $1.6200 in intra-day trade the report.
Tempest Therapeutics follows other major Healthcare sector earnings this month
Tempest Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar